On 9 July 2024, Roche received a temporary injunction order against Zydus from a previous bench of the Delhi High Court, restraining Zydus from marketing or selling their product Sigrima™, biosimilar to Roche’s Perjeta® (pertuzumab), till the next date of hearing.
The Delhi High Court has now dismissed an application filed by Roche seeking injunction against Zydus’ breast cancer drug Sigrima™.
Roche alleged that Zydus had infringed two of its patents for its HER2 positive breast cancer drug Perjeta®. In dismissing Roche’s application, the Court held that Roche had not established that Zydus’ product was likely to, or was actually infringing Roche’s patents.